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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not the use of
the drug Buprenorphine and Naloxone (Suboxone) is effective in suppressing opioid dependency
and its withdrawal symptoms, or is it simply a surrogate for the opiate with the same addictive
results.
Study Design: Review of three primary studies in the English language published in 2010 and
2011.
Data sources: Randomized, controlled and double blind clinical trials evaluating the
effectiveness of Suboxone in signs and symptoms of opioid withdrawal were found using the
EBSCO Host and Lexi-Comp databases.
Outcome(s) Measured: Likability of the drug versus the placebo using Visual Analog Scale
(VAS), side effects, withdrawal symptoms using Clinical Opiate Withdrawal Scale (COWS),
abuse potential, and drug questionnaires.
Results: Three randomized controlled trials were included in this review. Suboxone was shown

to be effective in the prevention of signs and symptoms of withdrawal. However, when
compared to heroin participants, were significantly less willing to take low or high dose
Suboxone again. Previous studies reported that addition of naloxone to bupornephrine reduced
the potential of misuse.
Conclusions: All three RCT proved the effectiveness of Suboxone in the management of signs
and symptoms of opioid withdrawal with no reports of misuse. Limitations in Middleton’s study
resulted in difficultly determining if the observed difference in abuse potential between
intranasal buprenorphine and Suboxone was accurate with the studies done. Strain’s study
showed that there was a significant decrease in observable withdrawal signs after administration
of Suboxone when compared to baseline. The higher progressive ratio breakpoint for high dose
Suboxone was similar to low dose bupornephrine in Comer’s study. This suggested that the
naloxone component attenuated the euphoric effects of buprenorphine, resulting in decrease
misuse potential.
Key Words: Suboxone, opioid, abuse, withdrawal
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INTRODUCTION
Opioid dependency is characterized by the continued use of opioids despite significant
opioid-induced problems. Dependency can result from the overuse of prescription drugs or from
illicit drug use.1This paper encompasses three randomized controlled trials comparing
buprenorphine/naloxone (Suboxone) effects versus placebo effects on patients going through
drug withdrawal, while also looking at the abuse potential for Suboxone alone. Suboxone is
known to be an effective opioid dependence pharmacotherapy, but there have been reports of
misuse as well.
This topic is relevant to practice everywhere because it is a disease that a practitioner in
any specialty will encounter. According to the Department of Health and Human Services,
approximately 213,000 individuals aged 12 years and older are dependent on or abuse heroin,
and 1,707,000 individuals 12 years and older are dependent on prescription pain medications.3
Not only is opioid dependence or abuse extremely common, the amount of medical costs is
astounding. In 1996, it was estimated that the total cost of heroin addiction, including medical
costs, were $21.9 billion, while also accounting for most emergency department visits.2 Opioid
dependence accounted for 66% of visits in the ED from 2004 to 2007.3 From 2005 to 2007, there
was a 55% increase in ED visits for drug-related suicide attempts involving opioids; 16% of ED
visits for drug-related suicide attempts in 2007 involved opioids.3 In 2000, the US Congress
passed the Drug Addiction Treatment Act, which allows qualified physicians to treat opioid
addiction with schedule III-V narcotics approved by the US Food and Drug Administration for
opioid dependence treatment.2 This allowed for opioid treatment outside of methadone clinics,
resulting in patients with opioid dependence history to be treated by their primary care physician.
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Opioid dependency is a national problem and can include misuse of morphine, heroin,
codeine, meperidine, and hydromorphine. When a patient takes these drugs they will feel an
initial “rush” which is followed by a sense of wellbeing. Physical signs to look for in a patient
you suspect is on opioids will be: pupillary constriction, respiratory depression, slurred speech,
hypotension, bradycardia, and hypothermia.4According to the DSM criteria, dependence is
considered when a patient has three or more of the following, occurring at any time in a 12month period: tolerance, withdrawal, repeated excessive use, persistent failed efforts to cut
down, excessive time spent trying to obtain substance, reduction in important social,
occupational, or recreational activities, and continued used despite awareness that substance is
the cause of psychological or physical difficulties.4Withdrawal symptoms include: anxiety,
pupillary dilation, diaphoresis, tachycardia, fever, diarrhea, insomnia, yawning, vomiting,
piloerection, muscle aches, seizures, hypertension and abdominal cramps.4
The recommended method of treatment for opioid dependence include: methadone,
buprenorphine, Suboxone, combined with therapy. For the purpose of this paper the focus will be
Suboxone, which can help reduce physical withdrawal symptoms and cravings. When a person
takes an opiate, the drug attaches to mu receptors, which then releases dopamine, which results
in pleasurable feelings.5 As the opioids leave the receptors, the pleasurable feelings start to fade
away and withdrawal symptoms, such as, cravings start to occur.5Suboxone contains two active
ingredients, buprenorphine and naloxone. Buprenorphine is a schedule III partial agonist at the
mu opioid receptor that will attach to the empty opioid receptors, thus reducing the withdrawal
symptoms.5There have been studies that show buprenorphine alone can have abuse liability, as it
can produce euphoria.4 Naloxone is an opioid antagonist that was added to buprenorphine in
effort to prevent the potential for intravenous misuse. Therefore, this method of treatment is
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being proposed to see if adding naloxone to buprenorphine will decrease the incidence of misuse
while also preventing withdrawal symptoms.
OBJECTIVE
The objective of this systematic review is to determine if the use of the drug Suboxone is
effective in suppressing opioid dependency and its withdrawal symptoms, or is it simply a
surrogate for the opiate with the same addictive results?
METHOD
In order to find adequate information for the research of this topic, a set of criteria was used
for the selection of studies selected. Common interventions among all of the studies included an
experimental group which received Suboxone or bupornephrine compared to the control group,
which received a placebo. The comparison interventions in each of the three randomized
controlled trials were the effects of the placebo pill versus the effects of Suboxone or
bupornephrine while the patient was going through withdrawal. Outcomes measured in the three
randomized control studies were the likability of the drug versus the placebo using Visual
Analog Scale (VAS), side effects, withdrawal symptoms using Clinical Opiate Withdrawal Scale
(COWS), and abuse potential.2,3,5 All studies included in this paper were randomized control
trials obtained from EBSCO between September 2012-January 2013. Key words used in
literature search were: “opioid dependence,” “opioid withdrawal,” “buprenorphine,” and
“naloxone”. All articles were published in peer-reviewed journals and were written in English.
Articles were carefully chosen based on their clinical relevance, along with following the criteria
of being patient-oriented evidence that matters. For demographics, inclusion and exclusion
criteria, and population refer to Table 1. Statistics reported in these studies included p-values and
ANOVA.
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Middleton’s study evaluated patients with opioid abuse that was confirmed by a urinalysis.
Intervention for this study was a randomized, double blinded, 3.5 week in-patient study. On
session days, subjects received a powder from crushed placebo, buprenorphine (2 or 8 mg) or
Suboxone (2/0.5 or 8/2).2 Baseline data collected 30 minutes prior and 6 hours after drug
administration.
Strain’s study was a randomized control trial in which placebo versus Suboxone was studied.
The population in this study was 74% male, average age 40 years old and 64% white.3The
intervention was started by giving patients 30 mg SC morphine to develop a baseline. After day
eight, patients were given Suboxone (4/1) at 9am, 11am, and 8pm, while another group was
given a matching placebo. Protocol allowed for flexible dosing for Suboxone between 12/3mg24/6 mg to control withdrawal symptoms.3
In Comer’s randomized control trial, patients were placed in a qualification phase, where
participants who did not self-administer intravenously at least 4 mg buprenorphine more
frequently than placebo were discontinued from the study.6 The next three weeks patients were
either given a placebo, Suboxone (4/1), or buprenorphine 2mg-16mg depending on withdrawal
symptoms.
Table 1.Demographics & Characteristics of Included Studies.
Study

Type

#Pts

Age
(yrs)

Inclusion Criteria
31 +/- 2.27 yrs
Good health per:

Middleton
(2011)

Double
blinded
RCT

12

31 +/2.27
yrs

Physical exam
ECG (normal)
Medical History
Lab tests
UA confirmed illicit
drug use

Exclusion Criteria
Seizure disorders
Respiratory
disorders
History of asthma
Head injury
HTN
CVD
Abnormal ECG
Req. daily
prescribed med.

W/D

2

Interventions
On session days, subjects
received a powder from
crushed placebo,
buprenorphine (2 or 8 mg) or
bup./naxolone (2/.5 or 8/2).

Baseline data collected 30
minutes prior and 6 hours
after drug administration
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18 - 65 yrs
DSM-IV
Strain
(2011)

RCT

38

25 - 56
yrs
(μ:
41yrs)

4

Induction of bup./naxolone
on the first day at: 4/1 mg
dosed at 9am, 11am, and 8
pm for a total of 12/3
bup./naxolone, another group
given a matching placebo.

7

2 week qualification phase
and 3 week experimental
phase.
Qualification phase: 2 mg
sublingual buprenorphine
Experimental phase: 1st
week: SL bup. stabilization
period
2ndwk: double-blind test

(-) pregnancy
MMSE >24

Patient on placebo
with COWS > 12

(-) oral herpes
No dental caries
No recent studies
Daily IV heroin

Comer
(2010)

Doubleblinded
RCT

19

21 - 45
yrs

Daily heroin expense:
$30-145
Duration: 2 - 32 yrs

Participants who did
not self-administer
IV 4 mg
buprenorphine more
frequently than
placebo were d/c
from the study

OUTCOMES MEASURED
Outcomes measured were those of patient-oriented evidence that matters. In Middleton’s
study subjective outcomes were measured with VAS, where zero equaled “not at all” and 100
equaled “extremely.”1 Addiction Research Center Inventory short form and street value
questionnaire were also completed. Strains study measured primary outcomes using COWS.
Measure of secondary outcomes included VAS, with ratings of “feeling high,” “good effects,”
and “bad effects.”3 Participants were specifically asked to rate how the drug made them feel
rather than how they felt in general.3 In Comer’s study, outcomes measured were comparing
control versus experimental in the following areas: “drug liking,” and potential abuse using drug
effects questionnaire, VAS, and subjective opioid withdrawal scale.6
RESULTS
In Middleton’s study, using VAS, participants were asked to rate “How much do you like
the drug?” Results showed significant dose-dependence effects (p<0.0001). Compared to the
placebo, a significant increase in ratings of “liking” was observed 45 minutes after
administration of Suboxone (8/2), with a Turkey test P< 0.05.2 However, low doses were not
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significantly different from the placebo. In table 2, peak analysis of VAS measures revealed a
significant dose effects for “high,” “drug effect,” “like,” “good,” and “bad” (p<0.01).2 Both
formulations produced a time and dose dependent increases on subjective effects. Patients
reported a higher street value for buprenorphine 8 mg compared to Suboxone 8/2mg, but these
differences were not statistically significant.2 Peak analyses revealed that all active doses
differed from the placebo, with a p-value of <0.5.2 Based on the tests done it is difficult to
determine if there is higher abuse potential between intranasal buprenorphine and Suboxone
when compared to placebo.
The incidence of adverse events occurred, but no serious side effects were noted. Table 3
notes adverse events that presented during this study. Along with those adverse events one
subject complained of blurred vision during the session.2
Table 2. Peak Scores for subjective measures (n=10)
Subjective VAS

B/N 2/0.5: mean (SEM)

Like
Drug Effect
High
Good
Bad

25 (6.10)
30.5 (5.62)
23.1 (6.38)
24.5 (6.13)
9.6 (3.32)

B/N 8/2mg: Mean (SEM)
43.6 (6.10)
36.3 (5.97)
35.5 (6.27)
35.5 (6.17)
8.4 (2.83)

Placebo
Mean (SEM)
2.7 (1.48)
4.1 (1.86)
3.3 (1.51)
3.3 (1.54)
.6 (0.50)

Table 3. Safety: Adverse Events
Side Effect
Vomiting
Constipation
Headache

Percent Affected
40%
50%
40%

The Strain study measured the primary outcomes using COWS, and secondary outcomes
using VAS. Prior to induction of the first soluble film COWS scores were elevated with a mean
of 9.6. and after administration of Suboxone the COWS scores decreased to a mean of 5.7, which
remained low for five days.3 The ratings showed that there was a significant decrease in
observable withdrawal signs when compared to baseline. Ratings of high, bad effects, and sick
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were measured by VAS and remained low throughout the treatment period. There were
significant time-related variations (p<0.0001) with a peak liking of Suboxone at 51.4.3
Safety evaluation was conducted throughout the study. Of the 38 participants, 18 of those
received Suboxone. Of those 18, four of the participants had mild non-ulcerous irritations of the
oral mucosa that were not present at baseline.3 One patient had elevation in liver enzyme tests;
however follow up tests showed a decline back to normal levels. Previous studies have noted that
patients with a history of Hepatitis C whom receive buprenorphine treatment have elevated liver
enzymes. However, no participants in this study with a history of Hepatitis C had elevated liver
enzymes. The results proved that the use of buprenorphine and Suboxone films to be safe and
effective methods for opioid dependency treatment.
Table 4.COWS Score Pre and Post Administration of B/N or Buprenorphine.
Pre-treatment COWS score
(mean)
Post-Treatment COWS score
(mean)

B/N 4/1mg
10.1

Buprenorphine
9.1

5.7

4.2

The randomized control study conducted by Comer included 12 participants who were
included in the final analysis. Based on mean drug progressive ratio breakpoints, reinforcing
effects for heroin, high dose Suboxone, low dose buprenorphine were greater when compared to
the placebo. Low dose Suboxone demonstrated reinforcing effects lower than that for heroin
(p=0.0001).6 High dose Suboxone had reinforcing effects that were also lower when compared to
heroin (p=0.055).6 When individual doses were compared, participants preferred intravenous
high dose buprenorphine over all other buprenorphine formulations. According to the Drug
Effects Questionnaire, participants reported a higher liking for heroin, high dose Suboxone and
low or high dose buprenorphine over the placebo (p <0.0001).6 For all buprenorphine
formulations participants were willing to take the drug again when compared to the placebo,
however, participants were significantly less willing to take low or high dose Suboxone again
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when compared to heroin. Results of VAS showed that low dose Suboxone was the only
formulation that differed significantly and had similar results when compared to the placebo.
Low dose Suboxone and the placebo did not significantly differ in the following categories: good
effects, feeling high, liking the drug, feeling sedated, and amount of money they would pay for
the drug. Table 5 displays the results for mean subjective VAS scores, where 0 equals “not at all”
and 100 equal “extremely.”
Seven adverse events were reported in participants. Adverse events that were encountered
included: urticaria, nausea, vomiting, dizziness, and chest discomfort.6 Most side effects were
mild and transient and resolved with any type of treatment.
Table 5. Mean subjective VAS
VAS measure
(mean +/- SE)
Good effects
High
Liked the Drug
Would pay
Bad effects

Placebo
1.75 ± 0.90
2.06±1.08
1.19±0.62
0.25±0.13
3.14±1.47

Low Dose
Suboxone
12.67±3.07
12.19±2.94
10.50±2.44
1.72±0.51
4.00±2.14

High Dose
Suboxone
30.61±4.20
31.56±3.65
27.28±3.97
5.81±0.91
5.03±3.49

Heroin
41.11±5.24
36.81±5.04
41.56±5.42
8.50±1.10
0.00±0.00

DISCUSSION
The three randomized controlled trials demonstrated the effectiveness of Suboxone in
response to withdrawal symptoms. However, results also showed that patients have similar
responses to Suboxone when compared to heroin. Although buprenorphine is believed to show
even closer results to that of heroin, it still leaves the question as to the abuse potential for
Suboxone.
In Middleton’s trial, based on the current results, it is not evident that observed
differences with regard to abuse potential between the formulations are clinically relevant at the
doses studied.2 When high doses of Suboxone were compared to the placebo, participants had a
better liking of the drugs, which leads one to believe the potential misuse. When compared to
buprenorphine, participants had a better liking of that, which shows that by adding naloxone to
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buprenorphine does help decrease the “high” effect. The doses used in this study were
considered lower doses, with Suboxone doses at 2/.5 and 8/2mg. It is noted that patients who are
going to misuse drugs are going to do so at higher dosings.2 Therefore, it would have benefited
researchers to give higher doses of Suboxone to test for abuse potential. Buprenorphine alone
could lead to misuse via the intranasal route due to the increase in euphoric effects, along with
the quicker onset of action.2Even though participants reported higher street value and drug liking
for buprenorphine, when compared to Suboxone, the subjective ratings and street values were
not statistically significant.2 Limitations noted in this study were the doses of buprenorphine and
Suboxone along with the small sample size of ten participants.
The results of the clinical trials done by Strain suggest that soluble film formulations
were effective in suppressing opioid withdrawal.3 Suboxone was able to attenuate signs and
symptoms of withdrawal without belief of addiction potential due to the effects of naloxone.
There was significant reduction in overall COWS scores, which demonstrates that the induction
of Suboxone is effective. Suboxone was shown to be effective in reducing withdrawal signs and
symptoms, while also having less abuse potential when compared to bupornephrine alone.3 A
pervious study done, received results from a questionnaire of 145 participants in a needle
exchange program. Of those 145 participants 8% abused Suboxone compared to the 82% who
reported abused bupornephrine.6 A limitation this trial could have benefited from was having a
longer stabilizations period using morphine, which would have strengthened the aspect of the
study design.5 Another limitation to this study was in respect to the absence of precipitated
withdrawal of symptoms and a fixed dose schedule of Suboxone. In a clinical setting a physician
will work with the patient and adjust dosing in regards to their withdrawal symptoms. Overall the
results of this study noted that Suboxone was effective and safe under the dose-induction period.
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Clear advantages of soluble film formulations is that they can have the can be given as a single
dose, in a soluble stripe form where physicians can easily track a dose of the medication.5 The
rapid solubility can be an advantage in setting where monitoring administration of the
medication is necessary.5
Comer’s study identified conditions under which Suboxone had less potential to be
abused intravenously when compared to buprenorphine or heroin.6 After completing the study it
was noted that participants were willing to pay a less amount of money for Suboxone when
compared to buprenorphine or heroin.6 There was a reduced administration by injection for
participants on higher maintenance doses, which suggests that Suboxone dosing is an important
factor in preventing misuse.6 If a patient is maintained on the correct dose and they are not
experiencing withdrawal signs and symptoms they are less likely to misuse the drug. When high
doses of intravenous Suboxone were injected it was comparable to the effects of heroin. The
higher progressive ratio breakpoint for high dose Suboxone was similar to low dose
bupornephrine.6 This suggests that in bupornephrine dependence injection drug users, the
naloxone component attenuated the euphoric effects of buprenorphine.6 This also leads
researcher to believe that Suboxone, when compared to bupornephrine, will indeed decrease the
misuse.6 The stringent criteria for enrollment and the selective population of opioid dependent
users resulted in a small, specific population of participants, which could result in a lack of trend
across the maintenance doses in subjective effects and might not be representative of the entire
opioid-dependent population.6
While Suboxone is commonly used across the United States for opioid dependency, there
are limitations to its use. In regards to insurance companies, there are some physicians that will
take any insurance and allow it to cover for the treatment of opioid dependence, while others will
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only take cash.5 With that being said, most insurance companies will cover Suboxone for
treatment of opioid dependency. The contraindications to the use of Suboxone are
hypersensitivities to bupornephrine or naloxone.7 Hypersensitivity reactions that have been
reported in the past are the following: bronchospasm, angioneurotic edema, and anaphylactic
shock.7 Suboxone is a pregnancy category C and is currently not used in patients who are
pregnant, due to the risk of neonatal withdrawal syndrome.7 It is also not recommended to take
Suboxone while breastfeeding because it is not known whether naloxone is excreted in breast
milk or not.7
CONCLUSION
In conclusion, these studies provide evidence that Suboxone is effective in preventing
signs and symptoms of opioid withdrawal symptoms with limited findings of misuse. In the
United States, Suboxone is available by prescription from qualified physicians and reports of
misuse have been limited.6 In Australia and Finland, the introduction of Suboxone has also been
associated with lower rates of misuse.6However, in further studies that do take place, a
recommendation that would benefit researchers would be the include a large population study
and high doses of Suboxone. Future studies of Suboxone should include the study of sublingual
films rather than tablets, primarily because this is what physicians are prescribing to their
patients. In order to study the abuse potential it would be effective to monitor the same
formulations given in the office. With any drug there is potential for misuse and abuse,
Suboxone has been proven to have lower abuse liability when compared to what was previously
available. The effects of naloxone have proven to be effective in blocking the effects of
bupornephrine, ultimately reducing the risk of misuse.4 Close monitoring by physicians and
practitioners, along with therapy, is imperative for success in treatment of opioid dependency.
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